Revisión sistemática

No clasificado

Año 2013
Revista Current medical research and opinion

Sin referencias

Cargando información sobre las referencias
Mostrar resumen

BACKGROUND:

Prior to the approval of the first erythropoiesis-stimulating agent (ESA) in the early 1990s, red blood cell transfusions were the primary means of treating severe chemotherapy-induced anemia (CIA), with little recourse for those with more mild forms of the condition. The introduction of the ESAs allowed treatment of mild-to-moderate CIA in patients with cancer. It has been a decade since darbepoetin alfa (DA), a second-generation ESA with a longer half-life, became available to patients with CIA.

OBJECTIVE AND METHODS:

We present a review of studies on DA in CIA, from its development through to the present day. Medline was searched for randomized clinical trials on DA. Additional trials and meta-analyses on ESAs were incorporated into this review when relevant.

RESULTS:

The first publications on DA generally focused on optimal dosing, efficacy and tolerability. In these, it was shown that DA is an effective and well tolerated treatment option to achieve hematopoietic response, regardless of dosing interval. Subsequently, the focus shifted towards meta-analyses on survival data of all ESAs. These reported conflicting results regarding mortality and/or disease progression. However, guidelines for ESA use were updated and, when followed, these make ESAs a well tolerated and effective tool for managing CIA.

CONCLUSIONS:

As the past decade has broadened our knowledge on the benefits and risks of CIA management, continued high-quality studies will help to optimize treatment with ESAs in order to maximize quality of life for these patients. The limitation of a literature review of this nature is the complete reliance on previously published research and the availability of these studies using the methodology outlined above.

Mostrar resumen

Revisión sistemática

No clasificado

Año 2016
Autores Steuber TD , Howard ML , Nisly SA
Revista The Annals of pharmacotherapy

Sin referencias

Cargando información sobre las referencias
Mostrar resumen

OBJECTIVE:

To assess the use of oral iron, intravenous (IV) iron, and erythropoiesis-stimulating agents (ESAs) for the prevention and management of perioperative anemia in elective orthopedic surgery patients, and to provide a clinical algorithm for use.

DATA SOURCES:

A PubMed and MEDLINE search was conducted from 1964 through March 2016 using the following search terms alone or in combination: orthopedic, surgery, elective, anemia, blood transfusion, iron, erythropoiesis-stimulating agents, and erythropoietin.

STUDY SELECTION AND DATA EXTRACTION:

All English-language prospective and retrospective human studies and meta-analyses evaluating oral iron, IV iron, or ESA alone or in combination in elective orthopedic surgery patients were evaluated, provided they reported blood transfusion outcomes.

DATA SYNTHESIS:

A total of 9 prospective and retrospective studies and 1 meta-analysis were identified and included. In the preoperative setting, administration of oral iron, IV iron, or ESA alone or in combination to correct underlying anemia led to significantly reduced transfusion rates. Transfusion requirements were generally less with combination therapy (ESA + oral or IV iron). In the short-term perioperative or postoperative period, use of oral or IV iron led to conflicting results, with some reporting a statistically significant reduction in blood transfusions, whereas others reported none.

CONCLUSIONS:

In elective orthopedic surgery, IV or oral iron with or without an ESA may provide benefit in prevention of postoperative anemia and results in blood transfusion reduction without significantly increasing the risk of adverse events. These agents should be considered at the lowest effective dose with emphasis on administration prior to planned surgery.

Mostrar resumen

Estudio primario

No clasificado

Año 1970
Autores Iyengar L , Apte SV
Revista The American journal of clinical nutrition
Cargando información sobre las referencias
Mostrar resumen

Este artículo no tiene resumen

Mostrar resumen

Estudio primario

No clasificado

Año 1998
Revista Nutrition Research
Cargando información sobre las referencias
Mostrar resumen

The objective of the present investigation was to study the effect of early prophylactic enteral administration of elemental iron, as ferrous sulfate, at the dose of 4 mg/kg/day to preterm neonates with a birth weight of less than 1600 g and a gestational age of 35 weeks, on early anemia of prematurity, and to determine the need for vitamin E supplementation (25 IU/day). Forty neonates were divided into 4 groups respectively receiving the following supplementations starting at 15 days of life: Group I, placebo; Group II, iron; Group III, iron + vitamin E; Group IV, vitamin E. Between 24 and 72 hours of life and at 2 months ± 5 days, each infant was evaluated for weight, length, head circumference, hemoglobin, hematocrit, reticulocytes, platelets, and red cell resistance to hydrogen peroxide. No significant differences were observed between groups for any of the parameters studied, suggesting that the dose of 4 mg/kg/day of iron and the use of vitamin E, 25 IU/day, had no effect on early anemia of prematurity.

Mostrar resumen

Revisión sistemática

No clasificado

Año 2012
Revista The oncologist

Sin referencias

Cargando información sobre las referencias
Mostrar resumen

BACKGROUND:

Anemia is a common manifestation in patients with cancer. Little is known about the frequency of and risk for anemia with targeted therapies used to treat solid tumors.

METHODS:

We performed a meta-analysis of randomized controlled trials of solid tumors by comparing targeted therapy (alone or in combination) with standard therapy alone to calculate the incidence and relative risk (RR) for anemia events associated with these agents. Overall, 24,310 patients were included in the analysis.

RESULTS:

The addition of targeted therapies to standard treatment (chemotherapy or placebo/best supportive care) increased the risk for all grades of anemia by 7%. The RR for all grades (incidence, 44%) and grades 1-2 (incidence, 38.9%) of anemia was higher with biological therapies alone but not when combined with chemotherapy. The risk was significant for erlotinib, trastuzumab, and sunitinib. Bevacizumab was associated with a lower risk for anemia. Anti-epidermal growth factor receptor, anti-human epidermal growth factor receptor 2, anti-vascular endothelial growth factor receptors, and tyrosine kinase inhibitors predicted RRs of 1.24, 1.20, 0.82, and 1.33, respectively, and all of these values were significant.

CONCLUSION:

Grade 1-2 anemia is frequently associated with biological agents. The risk is particularly associated with small-molecule tyrosine kinase inhibitors (gefitinib and erlotinib), breast cancer, and lung cancer. Erythropoiesis-stimulating agents are not labeled for use with targeted therapies (without chemotherapy) and the treatment is supportive only.

Mostrar resumen

Revisión sistemática

No clasificado

Año 2002
Revista BMC cancer

BACKGROUND:

This study was designed to evaluate if erythropoietin (EPO) is effective in the treatment of cancer related anemia, and if its effect remains unchanged when data are analyzed according to various clinical and methodological characteristics of the studies. We also wanted to demonstrate that cumulative meta-analysis (CMA) can be used to resolve uncertainty regarding clinical questions.

METHODS:

Systematic Review (SR) of the published literature on the role of EPO in cancer-related anemia. A cumulative meta-analysis (CMA) using a conservative approach was performed to determine the point in time when uncertainty about the effect of EPO on transfusion-related outcomes could be considered resolved.

PARTICIPANTS:

Patients included in randomized studies that compared EPO versus no therapy or placebo.

MAIN OUTCOME MEASURES:

Number of patients requiring transfusions.

RESULTS:

Nineteen trials were included. The pooled results indicated a significant effect of EPO in reducing the number of patients requiring transfusions [odds ratio (OR) = 0.41; 95%CI: 0.33 to 0.5; p < 0.00001;relative risk (RR) = 0.61; 95% CI.: 0.54 to 0.68]. The results remain unchanged after the sensitivity analyses were performed according to the various clinical and methodological characteristics of the studies. The heterogeneity was less pronounced when OR was used instead of RR as the measure of the summary point estimate. Analysis according to OR was not heterogeneous, but the pooled RR was highly heterogeneous. A stepwise metaregression analysis did point to the possibility that treatment effect could have been exaggerated by inadequacy in allocation concealment and that larger treatment effects are seen at hb level > 11.5 g/dl. We identified 1995 as the point in time when a statistically significant effect of EPO was demonstrated and after which we considered that uncertainty about EPO efficacy was resolved.

CONCLUSION:

EPO is effective in the treatment of anemia in cancer patients. This could have already been known in 1995 if a CMA had been performed at that time.

Mostrar resumen

Revisión sistemática

No clasificado

Año 2014
Revista Cochrane Database of Systematic Reviews
Cargando información sobre las referencias
Mostrar resumen

BACKGROUND:

Anaemia occurs when blood contains fewer red blood cells and lower haemoglobin levels than normal, and is a common complication among adults with chronic kidney disease (CKD). Although a number of approaches are applied to correct anaemia in adults with CKD, the use of androgen therapy is controversial.

OBJECTIVES:

The aim of this review was to determine the benefits and harms of androgens for the treatment of anaemia in adult patients with CKD.

SEARCH METHODS:

We searched CENTRAL, the Cochrane Renal Group's Specialised Register, the Chinese Biomedicine Database (CBM), CNKI, VIP and reference lists of articles without language restriction. The most recent search was conducted in August 2014.

SELECTION CRITERIA:

All randomised controlled trials (RCTs) that assessed the use of androgens for treating anaemia of CKD in adults were eligible for inclusion.

DATA COLLECTION AND ANALYSIS:

Two authors independently extracted data and assessed risk of bias in the included studies. Meta-analyses were performed using relative risk (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes, with 95% confidence intervals (CI).

MAIN RESULTS:

We included eight studies that reported data from 181 participants. Study quality was assessed as moderate in six studies, one was low quality, and one was high quality. The small number of included studies, and low participant numbers adversely influenced evidence quality overall.
We found limited evidence (1 study, 24 participants) to indicate that oxymetholone can increase haemoglobin (Hb) (MD 1.90 g/dL, 95% CI 1.66 to 2.14), haematocrit (HCT) (MD 27.10%, 95% CI 26.49 to 27.71), change in albumin (MD 4.91 g/L, 95% CI 3.69 to 6.13), alanine aminotransferase (ALT) (MD 54.50 U/L, 95% CI 43.94 to 65.06), and aspartate aminotransferase (AST) (MD 47.33 U/L, 95% CI 37.69 to 56.97); and decrease high-density lipoprotein (HDL) (MD -15.66 mg/dL, 95% CI -24.84 to -6.48). We also found that compared with erythropoietin alone, nandrolone decanoate plus erythropoietin may increase HCT (3 studies, 73 participants: MD 2.54%, 95% Cl 0.96 to 4.12). Compared with erythropoietin (1 study, 27 participants), limited evidence was found to suggest that nandrolone decanoate can increase plasma total protein (MD 0.40 g/L, 95% CI 0.13 to 0.67), albumin (MD 0.20 g/L, 95% CI 0.01 to 0.39), and transferrin (MD 45.00 mg/dL, 95% CI 12.61 to 77.39) levels. Compared with no therapy (remnant kidney), evidence was found to suggest that nandrolone decanoate can increase Hb (2 studies, 33 participants: MD 1.04 g/dL, 95% Cl 0.66 to 1.41) and HCT (1 study, 24 participants: MD 3.70%, 95% Cl 0.68 to 6.72). Compared with no therapy (anephric), evidence was found (1 study, 5 participants) to suggest that nandrolone decanoate can increase Hb (MD 1.30 g/dL, 95% Cl 0.57 to 2.03), but nandrolone decanoate did not increase HCT (MD 2.00%, 95% Cl -0.85 to 4.85).
However, oxymetholone was not found to reduce blood urea nitrogen (BUN), serum creatinine (SCr), cholesterol, or triglycerides; or increase plasma total protein, prealbumin, or transferrin. No evidence was found to indicate that nandrolone decanoate increased prealbumin or decreased BUN, SCr, AST, ALT, cholesterol, triglycerides, HDL or low-density lipoprotein (LDL). Adverse events associated with androgen therapy were reported infrequently.

AUTHORS' CONCLUSIONS:

We found insufficient evidence to confirm that use of androgens for adults with CKD-related anaemia is beneficial.

Mostrar resumen

Revisión sistemática

No clasificado

Año 2024
Revista An. Fac. Cienc. Méd. (Asunción)

Sin referencias

Cargando información sobre las referencias
Mostrar resumen

Introducción: La anemia se define como una afección en la cual el número de glóbulos rojos o la concentración de hemoglobina dentro de estos se encuentran por debajo del límite inferior, 11 gr/dl para menores entre 6 a 59 meses. La OMS calcula que a nivel mundial la anemia presenta una prevalencia del 42% en los niños menores de 5 años. Objetivos: Realizar una revisión panorámica de diversas publicaciones científicas acerca de los factores asociados a la anemia ferropénica en preescolares. Materiales y métodos: La revisión se realizó a través de la búsqueda electrónica de diversos artículos científicos relacionados con el tema. Se utilizó la pregunta

PEO:

¿Cuáles son los factores asociados a anemia ferropénica en lactantes y preescolares? Se seleccionaron los artículos publicados desde el 2017 hasta el 2022. Resultados: De los 48 artículos encontrados en la revisión, 33 fueron descartados por no cumplir con nuestros criterios de selección, quedando 15 artículos para esta revisión. Basado en 12 artículos revisados, se halló que los factores que se asocian a anemia en menores de 5 años eran por problemas socioeconómicos, déficit de micronutrientes altos en hierro en dieta, madre con antecedente de anemia, la edad materna, falta de educación, entre otros. Conclusión: Los factores predisponentes para la presencia de anemia ferropénica en los menores de 5 años más importantes fueron los relacionados con la edad materna, el nivel socioeconómico y educativo de la madre que conllevan el déficit de hierro del menor.

Mostrar resumen

Revisión sistemática

No clasificado

Año 2003
Revista Rev. panam. salud pública

Sin referencias

Cargando información sobre las referencias
Mostrar resumen

OBJETIVO:

Determinar la prevalencia de anemia en niños campesinos de edad escolar en la región amazónica de Ecuador.

MÉTODOS:

Se realizó un estudio transversal durante los meses de mayo a octubre de 2000 en dos cantones de la provincia de Orellana, al noreste de Ecuador. Se eligieron 17 escuelas aleatoriamente hasta completar el tamaño muestral deseado, que fue de 626 niños. Se recogieron los datos demográficos y antropométricos (peso y talla); se determinaron los valores de hemoglobina y de protoporfirina eritrocitaria, y se analizaron muestras de heces en busca de infestación por parásitos.

RESULTADOS:

La prevalencia general de anemia fue de 16,6 por ciento y de los escolares afectados, 75,5 por ciento tenían anemia por déficit de hierro. La prevalencia de desnutrición crónica moderada fue de 28,8 por ciento y la de desnutrición crónica grave, de 9,3 por ciento. Asimismo, se encontró una prevalencia de desnutrición aguda moderada de 8,4 por ciento y de desnutrición aguda grave de 3,4 por ciento. Las infecciones parasitarias fueron muy frecuentes (82,0 por ciento). Los parásitos más comunes fueron Entamoeba coli (30,3 por ciento) y Ascaris lumbricoides (25,0 por ciento). No se encontró ninguna relación entre la prevalencia de anemia y anemia por déficit de hierro por un lado, y los indicadores nutricionales o de infección parasitaria por el otro.

CONCLUSION:

La anemia no es un problema grave de salud pública en la población estudiada. No obstante, la elevada prevalencia de niños con desnutrición crónica apunta a la necesidad de mejorar las características de la dieta. La falta de asociación entre la prevalencia de desnutrición y la anemia podría deberse a una baja biodisponibilidad o absorción de hierro, más que a una ingestión insuficiente. Se necesitan estudios que evalúen el tipo de dieta consumida habitualmente por esta población

Mostrar resumen

Revisión sistemática

No clasificado

Año 2012
Revista Cochrane Database of Systematic Reviews
Cargando información sobre las referencias
Mostrar resumen

Background: Anaemia occurs in 68% to 77% of patients with advanced cancer, however, only a minority of patients who are admitted to a hospice receive a blood transfusion. It is unclear what the benefit of blood transfusion is in advanced cancer, who is most likely to respond and also for how long. Hence we conducted a systematic review to assess the use of blood transfusion in advanced cancer. Objectives: To synthesise the existing clinical evidence and summarise knowledge gaps regarding blood transfusions for treating anaemia in patients with advanced cancer. Search methods: We searched MEDLINE, EMBASE, CINAHL, Web of Science, ZETOC and CENTRAL in November 2011. In addition, we checked and citation-tracked the reference lists of all relevant studies and reports. We contacted investigators who were known to be researching this area for unpublished data or knowledge of the grey literature. Selection criteria: Randomised controlled trials (RCTs), before and after studies and interrupted time series (ITS) studies in adults and children, reporting the outcome of blood transfusions in advanced cancer. Data collection and analysis: Two independent (NP and AH) review authors extracted data and quality scored studies. There were insufficient data to carry out an analysis. Main results: No RCTs were found. We identified 12 before and after studies which included 653 participants and showed a subjective response rate of 31% to 70%. Five studies specifically assessed response using a range of fatigue scales which indicated an early response post transfusion, which was beginning to wane by day 14. Similar results were found for breathlessness. Overall survival ranged from two to 293 days but there was a significant proportion of participants (23% to 35%) who died within two weeks of their transfusion. Authors' conclusions: Higher-quality studies are required to determine the effectiveness of blood transfusion at the end of life and, in particular, to determine which patients are most likely to respond and which are not, and the duration of any response. Potential harms of blood transfusion at the end of life (indicated by high 14-day mortality) need to be distinguished from inappropriate transfusion in patients who are dying from advanced cancer.

Mostrar resumen